Transactions
3
Insider / TANDEM DIABETES CARE INC
ROBERTSON REBECCA B
Director at TANDEM DIABETES CARE INC
- Company
- TANDEM DIABETES CARE INC
- Ticker
- TNDM
- First filing on record
- May 22, 2026
- Latest trade on record
- May 21, 2026
- SEC filings
- EDGAR ↗
ROBERTSON REBECCA B, Director at TANDEM DIABETES CARE INC, has disclosed 3 transactions in TNDM since May 22, 2026: 0 purchases (0 open-market buys) and 0 sales, worth about $0 at the reported prices. The latest was filed May 22, 2026, 1 day after the trade.
Open-market buys
0
Sales
0
Avg. disclosure lag
1.3d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months ROBERTSON REBECCA B reported 3 transactions that were neither a purchase nor a sale, such as stock awards, option exercises or shares withheld for tax.
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| M | Option exercise or conversion | 2 | 17,518 | — |
| A | Grant or award | 1 | 10,220 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 3 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| TNDM | Option / conversion M | May 21, 2026 | May 22, 2026 | 1d | 8,759 | — | — | derivative | Form 4 ↗ | |
| TNDM | Other A | May 20, 2026 | May 22, 2026 | 2d | 10,220 | — | — | derivative | Form 4 ↗ | |
| TNDM | Option / conversion M | May 21, 2026 | May 22, 2026 | 1d | 8,759 | — | — | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| May 22, 2026 | Form 4 | 0001438133-26-000074 | 3 | published | EDGAR ↗ |
Other insiders at TANDEM DIABETES CARE INC
- Hansen Shannon Marie EVP & Chief Legal Officer 36 rows
- Gasser Elizabeth Anne EVP, Chief Strategy Officer 34 rows
- Carpenter Rick Chief Technology Officer 33 rows
- Morrison Susan EVP & Chief Admin. Officer 29 rows
- Sheridan John F PRESIDENT & CEO 29 rows
- Vosseller Leigh EVP & CHIEF FINANCIAL OFFICER 29 rows
- Kyrillos Jean-Claude EVP & Chief Operating Officer 24 rows
- Novara Mark David EVP & CHIEF COMMERCIAL OFFICER 20 rows
- Allen Dick Insider 3 rows
- Cha Myoungil Director 3 rows
Everyone on file, with contracts and lobbying under the company's name: TANDEM DIABETES CARE INC.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 1 | 3 | May 22, 2026 | May 22, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.